DelveInsight, a leading market research and consulting firm, has recently published an in-depth report on the Ankylosing Spondylitis (Bekhterev’s Disease) pipeline, providing valuable insights into emerging therapies, companies, and future outlooks.

 

DelveInsight’s, “Ankylosing Spondylitis (Bekhterev’s Disease) Pipeline Insight 2023” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Ankylosing Spondylitis (Bekhterev’s Disease) pipeline landscape. It covers the Ankylosing Spondylitis (Bekhterev’s Disease) pipeline drug profiles, including Ankylosing Spondylitis (Bekhterev’s Disease) clinical trials and nonclinical stage products. It also covers the Ankylosing Spondylitis (Bekhterev’s Disease) therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

To explore more information on the latest breakthroughs in the Ankylosing Spondylitis (Bekhterev’s Disease) Pipeline treatment landscape of the report, click here @ Ankylosing Spondylitis (Bekhterev’s Disease) Pipeline Outlook

 

Key Takeaways from the Ankylosing Spondylitis (Bekhterev’s Disease) Pipeline Report

• DelveInsight’s Ankylosing Spondylitis (Bekhterev’s Disease) Pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for Ankylosing Spondylitis (Bekhterev’s Disease).
• The leading Ankylosing Spondylitis (Bekhterev’s Disease) Companies include Fresenius Kabi, Shanghai Henlius Biotech, Pfizer, Fujifilm Kyowa Kirin Biologics, Hetero Biopharma, Bio-Thera Solutions, Amgen, CinnaGen, Zydus cedilla, Cadila Pharmaceuticals, Sandoz, Innovent Biologics, Torrent Pharmaceuticals, Cipla, Emcure Pharmaceuticals, Biogen, Boehringer Ingelheim, Zhejiang Hisun Pharmaceuticals, Biocad, AbbVie, Mycenax Biotech, Celltrion, UCB Biopharma, Gilead Sciences, Sun Pharma Global, Jiangsu HengRui Medicine Co., Ltd., Izana Bioscience, Suzhou Zelgen Biopharmaceuticals, Iltoo Pharma, Kinevant Sciences, Qyuns Therapeutics, Akeso Biopharma, Nimbus Therapeutics, Enzene Biosciences, Xbrane Biopharma, Dice molecules, and others
• Promising Ankylosing Spondylitis (Bekhterev’s Disease) Pipeline Therapies include infliximab, Etanercept, sulphasalazine (SSZ), prefilled liquid etanercept (Yisaipu), Celecoxib 200 milligrams, Golimumab, and others
• CC-99677 is a novel, oral, selective mk2 inhibitor with sustainable multicytokine inhibitor for the treatment of AS and other inflammatory diseases. The mitogen-activated protein kinase-activated protein kinase-2 (MK2) pathway is activated downstream of p38, and activation of MK2 increases the stability and translation of mRNA of proinflammatory factors (e.g., TNF-α, IL-17, IL-6). Inhibitors of p38 are associated with tachyphylaxis in patients with RA and other inflammatory diseases, where early reduction in ex vivo production of cytokines, such as TNF-α, or endogenous inflammatory markers, such as CRP, did not persist despite continued treatment. Thus, p38 inhibitors have not advanced in clinical development. Targets downstream of p38 have been identified to avoid these limitations.
• Bimekizumab (UCB4940) is the first humanized monoclonal IgG1 antibody that potently and selectively neutralizes IL-17A and IL-17F. These two key proinflammatory cytokines share similar biological functions and structural homology. IL-17A and IL-17F are the most closely related members of the IL17 family of cytokines. They are both co-expressed at sites of inflammation and have overlapping proinflammatory functions. Both IL-17A and IL-17F can independently cooperate with other inflammatory mediators to drive chronic inflammation and tissue destruction. This therapeutic candidate is in the Phase III stage of development to treat patients with ankylosing spondylitis (AS). The company is using the subcutaneous route of administration for AS.

 

For further information, refer to the detailed Ankylosing Spondylitis (Bekhterev’s Disease) Unmet Needs, Ankylosing Spondylitis (Bekhterev’s Disease) Market Drivers, and Ankylosing Spondylitis (Bekhterev’s Disease) Market Barriers, click here for Ankylosing Spondylitis (Bekhterev’s Disease) Ongoing Clinical Trial Analysis

 

Ankylosing Spondylitis (Bekhterev’s Disease) Overview

Ankylosing Spondylitis (Bekhterev’s Disease) (AS) is a form of arthritis that primarily affects the spine. It causes severe inflammation of the spinal joints (Vertebrae) that can lead to chronic pain and discomfort. Ankylosing Spondylitis (Bekhterev’s Disease) also cause pain, inflammation in other parts of the body such as the shoulders, hips, ribs, heels and small joints of the hands and feet.

 

Request a sample and discover the recent advances in Ankylosing Spondylitis (Bekhterev’s Disease) Ongoing Clinical Trial Analysis and Medications, click here @ Ankylosing Spondylitis (Bekhterev’s Disease) Treatment Landscape

 

Ankylosing Spondylitis (Bekhterev’s Disease) Emerging Drugs

 

• Tofacitinib: Pfizer

Tofacitinib, sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. By inhibiting JAKs, tofacitinib prevents the phosphorylation and activation of STATs. It is in Preregistration Phase.

• Bimekizumab: UCB Biopharma

Bimekizumab is an investigational humanized monoclonal IgG1 antibody that selectively inhibits both IL-17A and IL-17F. Bimekizumab binds to and neutralizes IL-17A and IL-17F, preventing their interactions with the IL-17 receptors expressed on keratinocytes, fibroblast-like synoviocytes, endothelial cells, chondrocytes and osteoblasts. It is in Phase III of clinical trial.

 

Dive deep into rich insights for drugs for Ankylosing Spondylitis (Bekhterev’s Disease) Market Drivers and Ankylosing Spondylitis (Bekhterev’s Disease) Market Barriers, click here @ Ankylosing Spondylitis (Bekhterev’s Disease) Unmet Needs and Analyst Views

 

Ankylosing Spondylitis (Bekhterev’s Disease) Pipeline Therapeutics Assessment

There are approx. 40+ key companies which are developing the therapies for Ankylosing Spondylitis (Bekhterev’s Disease). The companies which have their Ankylosing Spondylitis (Bekhterev’s Disease) drug candidates in the most advanced stage, i.e. Preregistration include, Pfizer.

 

Scope of the Ankylosing Spondylitis (Bekhterev’s Disease) Pipeline Report

• Coverage- Global
• Ankylosing Spondylitis (Bekhterev’s Disease) Companies- Fresenius Kabi, Shanghai Henlius Biotech, Pfizer, Fujifilm Kyowa Kirin Biologics, Hetero Biopharma, Bio-Thera Solutions, Amgen, CinnaGen, Zydus cedilla, Cadila Pharmaceuticals, Sandoz, Innovent Biologics, Torrent Pharmaceuticals, Cipla, Emcure Pharmaceuticals, Biogen, Boehringer Ingelheim, Zhejiang Hisun Pharmaceuticals, Biocad, AbbVie, Mycenax Biotech, Celltrion, UCB Biopharma, Gilead Sciences, Sun Pharma Global, Jiangsu HengRui Medicine Co., Ltd., Izana Bioscience, Suzhou Zelgen Biopharmaceuticals, Iltoo Pharma, Kinevant Sciences, Qyuns Therapeutics, Akeso Biopharma, Nimbus Therapeutics, Enzene Biosciences, Xbrane Biopharma, Dice molecules, and others
• Ankylosing Spondylitis (Bekhterev’s Disease) Pipeline Therapies- infliximab, Etanercept, sulphasalazine (SSZ), prefilled liquid etanercept (Yisaipu), Celecoxib 200 milligrams, Golimumab, and others.
• Ankylosing Spondylitis (Bekhterev’s Disease) Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Ankylosing Spondylitis (Bekhterev’s Disease) Mergers and acquisitions, Ankylosing Spondylitis (Bekhterev’s Disease) Licensing Activities @ Ankylosing Spondylitis (Bekhterev’s Disease) Emerging Drugs, and Recent Trends

 

Table of Content

1. Introduction
2. Executive Summary
3. Ankylosing Spondylitis (Bekhterev’s Disease): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Ankylosing Spondylitis (Bekhterev’s Disease)– DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Ankylosing Spondylitis (Bekhterev’s Disease) Collaboration Deals
9. Late Stage Products (Registered/Launch)
10. MSB11022: Fresenius Kabi
11. Late Stage Products (Preregistration)
12. Tofacitinib: Pfizer
13. Drug profiles in the detailed report…..
14. Late Stage Products (Phase III)
15. Bimekizumab: UCB Biopharma
16. Drug profiles in the detailed report…..
17. Mid Stage Products (Phase II/III)
18. Tildrakizumab: Sun Pharma Global
19. Drug profiles in the detailed report…..
20. Mid Stage Products (Phase II)
21. Namilumab: Izana Bioscience
22. Drug profiles in the detailed report…..
23. Early Stage Products (Phase I)
24. KIN-1901: Kinevant Sciences
25. Drug profiles in the detailed report…..
26. Preclinical Stage Products
27. Xcimzane: Xbrane Biopharma
28. Drug profiles in the detailed report…..
29. Discovery Stage Products
30. DNA-encoded library (DEL) technology: Dice molecules
31. Inactive Products
32. Ankylosing Spondylitis (Bekhterev’s Disease) Key Companies
33. Ankylosing Spondylitis (Bekhterev’s Disease) Key Products
34. Ankylosing Spondylitis (Bekhterev’s Disease)- Unmet Needs
35. Ankylosing Spondylitis (Bekhterev’s Disease)- Market Drivers and Barriers
36. Ankylosing Spondylitis (Bekhterev’s Disease)- Future Perspectives and Conclusion
37. Ankylosing Spondylitis (Bekhterev’s Disease) Analyst Views
38. Ankylosing Spondylitis (Bekhterev’s Disease) Key Companies
39. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services